Terminology Service < Semantic Lookup Platform

All terms in EFO

Label	Id	Description
AP4-related intellectual disability and spastic paraplegia	MONDO_0017241	[A disorder that presents with spastic paraplegia and intellectual disability in which the cause of the disease is a mutation in the AP4B1 gene.]
C-C motif chemokine 21 measurement	EFO_0008048	[quantification of the amount of C-C motif chemokine 21 in a sample]
C-C motif chemokine 23 measurement	EFO_0008049	[quantification of the amount of C-C motif chemokine 23 in a sample]
carnitine	CHEBI_17126	[An amino-acid betaine that is butanoate substituted with a hydroxy group at position C-3 and a trimethylammonium group at C-4.]
C-C motif chemokine 16 measurement	EFO_0008044	[quantification of the amount of C-C motif chemokine 16 in a sample]
C-C motif chemokine 17 measurement	EFO_0008045	[quantification of the amount of C-C motif chemokine 17 in a sample]
hexanoate	CHEBI_17120	[A short-chain fatty acid anion that is the conjugate base of hexanoic acid (also known as caproic acid).]
C-C motif chemokine 18 measurement	EFO_0008046	[quantification of the amount of C-C motif chemokine 18 in a sample]
C-C motif chemokine 19 measurement	EFO_0008047	[quantification of the amount of C-C motif chemokine 19 in a sample]
3- 4-hydroxyphenyl lactate measurement	EFO_0021008	[Quantification of the amount of 3- 4-hydroxyphenyl lactate in a sample.]
3-3-hydroxyphenylpropionate measurement	EFO_0021007	[Quantification of the amount of 3-3-hydroxyphenylpropionate in a sample.]
lamina propria of large intestine	UBERON_0011189	[A lamina propria that is part of a large intestine.]
3-methoxytyrosine measurement	EFO_0021009	[Quantification of the amount of 3-methoxytyrosine in a sample.]
docosapentaenoate n3 DPA; 22:5n3 measurement	EFO_0021048	[Quantification of the amount of docosapentaenoate n3 DPA; 22:5n3 in a sample.]
docosahexaenoate DHA; 22:6n3 measurement	EFO_0021047	[Quantification of the amount of docosahexaenoate DHA; 22:6n3 in a sample.]
eicosapentaenoate EPA; 20:5n3 measurement	EFO_0021049	[Quantification of the amount of eicosapentaenoate EPA; 20:5n3 in a sample.]
palmitoylcarnitine measurement	EFO_0021044	[Quantification of the amount of palmitoylcarnitine in a sample.]
oleoylcarnitine measurement	EFO_0021043	[Quantification of the amount of oleoylcarnitine in a sample.]
paraneoplastic cerebellar degeneration	MONDO_0044877	[A rare, immune-mediated disorder characterized by cerebellar degeneration due to the presence of an often undetected malignancy (usually carcinoma or lymphoma) in an anatomic site other than the cerebellum. Signs and symptoms include progressive ataxia, dysarthria, and nystagmus.]
dihomo-linolenate 20:3n3 or n6 measurement	EFO_0021046	[Quantification of the amount of dihomo-linolenate 20:3n3 or n6 in a sample.]